Halozyme upgraded to Buy from Neutral at UBS UBS transitioned coverage on Halozyme with a Buy rating from a Neutral rating. The firm upgraded shares due to valuation and is more bullish on the PEGPH20 program following the recently removed clinical hold and believes the Herceptin-SC launch is tracking well and provides near-term support and strong uptake. Price target raised to $16 from $%14.
News For HALO From The Last 14 Days
Check below for free stories on HALO the last two weeks.